Evidence map›Paper›PMID 34046602›Full record

ArticleRSC medicinal chemistry2021

Identification of P218 as a potent inhibitor of

Gustavo P Riboldi, Rachael Zigweid, Peter J Myler, Stephen J Mayclin, Rafael M Couñago, Bart L Staker

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Unlocking Opportunities forACS infectious diseases · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Gustavo P RiboldiCentro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP) Campinas SP 13083-875 Brazil rafael.counago@unicamp.br.ORCID https://orcid.org/0000-0002-5303-308X
Rachael ZigweidCenter for Infectious Disease Research, Seattle Children's Research Institute Seattle Washington 98109 USA bart.staker@seattlechildrens.org.
Peter J MylerCenter for Infectious Disease Research, Seattle Children's Research Institute Seattle Washington 98109 USA bart.staker@seattlechildrens.org.
Stephen J MayclinSeattle Structural Genomics Center for Infectious Disease (SSGCID) Seattle Washington 98109 USA.
Rafael M CouñagoCentro de Química Medicinal (CQMED), Centro de Biologia Molecular e Engenharia Genética (CBMEG), Universidade Estadual de Campinas (UNICAMP) Campinas SP 13083-875 Brazil rafael.counago@unicamp.br.ORCID https://orcid.org/0000-0003-1847-5090
Bart L StakerCenter for Infectious Disease Research, Seattle Children's Research Institute Seattle Washington 98109 USA bart.staker@seattlechildrens.org.
Center for Infectious Disease Research · USUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

NIAID NIH HHS HHSN272201700059CWellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34046602
PMCPMC8130613
OpenAlexW3093738953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.